Envestnet Portfolio Solutions Inc. Sells 2,138 Shares of West Pharmaceutical Services, Inc. $WST

Envestnet Portfolio Solutions Inc. lowered its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 31.3% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,694 shares of the medical instruments supplier’s stock after selling 2,138 shares during the quarter. Envestnet Portfolio Solutions Inc.’s holdings in West Pharmaceutical Services were worth $1,231,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in WST. Asset Management One Co. Ltd. grew its position in West Pharmaceutical Services by 16.7% during the third quarter. Asset Management One Co. Ltd. now owns 69,775 shares of the medical instruments supplier’s stock valued at $18,304,000 after acquiring an additional 10,009 shares during the last quarter. North Growth Management Ltd. boosted its stake in shares of West Pharmaceutical Services by 17.2% in the 3rd quarter. North Growth Management Ltd. now owns 34,000 shares of the medical instruments supplier’s stock valued at $8,930,000 after purchasing an additional 5,000 shares in the last quarter. Amundi grew its holdings in shares of West Pharmaceutical Services by 83.4% during the 2nd quarter. Amundi now owns 502,831 shares of the medical instruments supplier’s stock valued at $111,236,000 after purchasing an additional 228,696 shares during the last quarter. Caxton Associates LLP bought a new position in shares of West Pharmaceutical Services during the 2nd quarter valued at $1,610,000. Finally, Birch Hill Investment Advisors LLC raised its position in West Pharmaceutical Services by 87.4% in the 3rd quarter. Birch Hill Investment Advisors LLC now owns 136,470 shares of the medical instruments supplier’s stock worth $35,800,000 after purchasing an additional 63,638 shares during the period. 93.90% of the stock is currently owned by hedge funds and other institutional investors.

West Pharmaceutical Services Price Performance

WST opened at $240.50 on Wednesday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.18 and a current ratio of 2.87. The stock has a market capitalization of $17.30 billion, a PE ratio of 35.63, a price-to-earnings-growth ratio of 3.32 and a beta of 1.17. The stock’s 50 day moving average price is $269.92 and its 200-day moving average price is $261.29. West Pharmaceutical Services, Inc. has a 52-week low of $187.43 and a 52-week high of $348.90.

West Pharmaceutical Services Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, February 4th. Stockholders of record on Wednesday, January 28th will be given a $0.22 dividend. This represents a $0.88 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Wednesday, January 28th. West Pharmaceutical Services’s dividend payout ratio (DPR) is currently 13.04%.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on WST shares. KeyCorp raised their price objective on West Pharmaceutical Services from $325.00 to $350.00 and gave the company an “overweight” rating in a research note on Friday, October 24th. Barclays raised their price target on West Pharmaceutical Services from $275.00 to $325.00 and gave the stock an “equal weight” rating in a research report on Monday, October 27th. Morgan Stanley started coverage on West Pharmaceutical Services in a research report on Monday, December 1st. They issued an “equal weight” rating and a $285.00 price objective for the company. TD Cowen started coverage on West Pharmaceutical Services in a research note on Wednesday, October 29th. They set a “buy” rating for the company. Finally, Wall Street Zen raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research note on Saturday, December 20th. Three research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, West Pharmaceutical Services has a consensus rating of “Buy” and a consensus price target of $335.78.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.